Koers Cannex Capital Holdings Inc Canadian Securities Exchange
Aandelen
CA13768L1085
Farmaceutische producten
Omzet 2024 * | 120 mln. 165 mln. 112 mln. | Omzet 2025 * | - | Marktkapitalisatie | 106 mln. 146 mln. 99,62 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 0,89 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 0% |
Recentste transcriptie over Cannex Capital Holdings Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 38 | - | |
Andrew Thut
CEO | Chief Executive Officer | 50 | 01-10-14 |
Karl Chowscano
PSD | President | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rob Hunt
CHM | Chairman | 51 | 12-04-22 |
Anthony Dutton
PRN | Corporate Officer/Principal | 66 | - |
Chetan Gulati
BRD | Director/Board Member | 46 | 01-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+39,33% | 6,11 mld. | |
-18,38% | 4,35 mld. | |
-9,17% | 3,18 mld. | |
+3,98% | 3,16 mld. | |
-3,41% | 2,51 mld. | |
+48,74% | 1,98 mld. | |
-4,82% | 1,74 mld. | |
-1,24% | 1,63 mld. | |
-8,96% | 1,6 mld. |